United States · FDA National Drug Code directory
omalizumab
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 17088-0268_9d4e9303-e65f-4ae5-9c78-1a9b665262dd
- Product NDC
- 17088-0268
- Form
- INJECTION, SOLUTION
- Composition / generic term
- omalizumab
- Labeler
- Novartis Pharma Stein AG
- Marketing category
- DRUG FOR FURTHER PROCESSING
- Marketing start / end (source format)
- 20180928
- Source listing expiry
- 20261231
Source-listed ingredients
- OMALIZUMAB — 75 mg/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- .5 mL in 1 SYRINGE, GLASS (17088-0268-1) · 17088-0268-1
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →